Medical Pharmacology: Diabetes Management Practice Questions
Click on the correct answer.
Nateglinide (Starlix) is described as a D-phenylalanine derivative
that blocks K+ATP channels.
True
False
Pharmacological characteristic(s) of nateglinide (Starlix) includes/includes:
Primarily utilized by IV administration to increase insulin secretion.
Stimulates insulin secretion by blocking amino acid transport.
Both
Neither
Primary therapeutic effect associated with nateglinide administration:
Reduction of systemic blood pressure, with a greater effect on diastolic pressures versus systolic pressures.
Reduction of EGFR (glomerular filtration rate)
Reduces increased glucose levels following meals in type II diabetic patients
A & B
B & C
A, B & C
Comparison of nateglinide with other oral antidiabetic drugs:
More rapid promotion of enhanced insulin secretion.
Reduced duration of increased insulin secretion.
Both
Neither
Pharmacokinetic characteristics/characteristics of nateglinide (Starlix):
Rapid intestinal absorption
Plasma peak drug levels noted within the first hour following
administration.
Both
Neither
Notable side effects following nateglinide administration:
Weight gain
Hypoglycemia
Both
Neither
Nateglinide metabolism: primary route of metabolism is hepatic (liver) associated with cytochrome P450 isoforms CYP2C9 and CYP3A4. Glucuronide acid conjugates have also been found.
True
False
Nateglinide is effective when given as monotherapy and also if combined with "non-secretagogue" oral medications, metformin as an example.
True
False
Nateglinide may be used in patients who are elderly and in patients exhibiting renal impairment.
True
False
Nateglinide pharmacokinetics:
Peak effect occurs in about an hour.
Duration of action is about 4 hours
Elimination half-life is about an hour and a half.
A & B
B & C
A, B & C
Among these adverse effects, the one most likely to occur:
Dizziness (CNS)
Flu-like presentations
Upper respiratory infection
All of the above side effects occur with equal frequency.
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Powers A D'Alessio D Chapters 47:
Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and
Hypoglycemia in Goodman & Gilman's: The Pharmcological
Basis of Therapeutics, 13e, (Brunto LL Hilal-Dandan R Knollmann
BC, eds) McGraw-Hill Education, 2018.
Masharani U Diabetes
Mellitus (27-01) in Current Medical Diagnosis & Treatment (Papadakis
MA McPhee SJ Rabow MW McQuaid KR, eds) 61e McGraw Hill 2022.
Masharani U Kroon L
Chapter 41: Pancreatic Hormones & Glucose-Lowering Drugs
in Basic & Clinical Pharmacology (Katzung BG, Editor; Vanderah
TW, Associate editor) 15e McGraw Hill 2021.